|
Status |
Public on Mar 27, 2024 |
Title |
DNA methylation in PM154 decitabine treated |
Sample type |
SRA |
|
|
Source name |
PM154
|
Organism |
Homo sapiens |
Characteristics |
cell line: PM154 treatment: decitabine treatment
|
Growth protocol |
The medium for 22Rv1 cell lines is RPMI-1640 Medium supplumented with 10% fetal bovine serum for 22Rv1 cell line and for PM154 is prostate specific media using advanced DMEM.
|
Extracted molecule |
genomic DNA |
Extraction protocol |
Total genomic DNA was extracted from PDXs using QIAamp DNA Mini Kit (QIAGEN). Illumina
|
|
|
Library strategy |
Bisulfite-Seq |
Library source |
genomic |
Library selection |
Reduced Representation |
Instrument model |
Illumina NovaSeq 6000 |
|
|
Description |
YY2
|
Data processing |
restriction enzyme treatment methylation library preparetion bisulfite conversion sequencing
|
|
|
Submission date |
Oct 18, 2022 |
Last update date |
Mar 27, 2024 |
Contact name |
Yasutaka Yamada |
E-mail(s) |
yasutaka_yamada@dfci.harvard.edu
|
Phone |
8574988355
|
Organization name |
Dana-Farber Cancer Institute
|
Department |
Medical Oncology
|
Lab |
Beltran
|
Street address |
44 Binney street
|
City |
Boston |
State/province |
MA |
ZIP/Postal code |
02115 |
Country |
USA |
|
|
Platform ID |
GPL24676 |
Series (2) |
GSE216050 |
DNA methylation as a therapeutic target in RB1 deficient and neuroendocrine prostate cancer and rational co-targeting with B7-H3 [RRBS] |
GSE216054 |
DNA methylation as a therapeutic target in RB1 deficient and neuroendocrine prostate cancer and rational co-targeting with B7-H3 |
|
Relations |
BioSample |
SAMN31357868 |
SRA |
SRX17947148 |